Bio-Rad Laboratories, Inc. BIO-B

Full chart Compare
Set alert

Price alert · BIO-B

All alert types
379.50 USD 0.00 (+0.00%)

Oct 27, 2026, 2:37 PM EDT

379.50 Day range 379.50
244.54 52-week range 379.50
YTD
+22.14%
1 year
+25.19%
Market cap
10.15B
Revenue (ttm)
2.59B
Profit margin
8.59%
EPS (ttm)
7.89
Shares out
5.06M
P/E ratio
48.10
YTD return
+22.14%
1-year return
+25.19%
Volume
12
Avg volume
7
Open
379.50
Previous close
379.50
Day's range
379.50 – 379.50
52-week range
244.54 – 379.50
Beta
1.06
Earnings date
Nov 4, 2026

2Y +44.65 (+13.33%)

250300350Jan 25Jun 25Nov 25Mar 26Aug 26379.50

Key statistics

Enterprise value
9.90B
PEG ratio
4.23
Price / sales
3.92
Price / book
1.41
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-0.10%
Free cash flow
283.19M
Total cash
1.62B
Total debt
1.37B
Return on equity
3.11%
Short % of float
0.00%
50-day average
366.35
200-day average
311.38

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate 0.00.

Earnings history

Earnings

BIO-B recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 30, 20262.23———
Aug 4, 2026Jun 30, 20261.782.62+0.84+47.19%
Apr 30, 2026Mar 31, 20262.011.89-0.12-5.97%
Feb 12, 2026Dec 31, 20252.692.51-0.18-6.69%
Oct 29, 2025Sep 30, 20251.892.26+0.37+19.58%
Jul 31, 2025Jun 30, 20251.752.61+0.86+49.14%

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
bio-rad.com

News

Your note

Sign in to keep a note on BIO-B — it syncs with the Stock Master app.

Institution ownership

BIO-B institution ownership
Holder% heldSharesValueReported
Flow Traders U.S. LLC0.02%760288.42KJun 29, 2026
Morgan Stanley0.01%712270.20KJun 29, 2026
Whittier Trust Company0.00%16060.72KJun 29, 2026
UBS Group AG0.00%134.93KJun 29, 2026
Wells Fargo & Company0.00%17064.52KJun 29, 2026

Fund ownership

BIO-B fund ownership
Holder% heldSharesValueReported
Gabelli Global Small & Mid Cap Value Trust0.00%15056.92KSep 29, 2026